Response Genetics, Inc.  

(Public, NASDAQ:RGDX)   Watch this stock  
Find more results for Sam Chawla�
0.540
+0.020 (3.85%)
Real-time:   12:50PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.50 - 0.54
52 week 0.48 - 1.73
Open 0.50
Vol / Avg. 63,998.00/154,010.00
Mkt cap 20.55M
P/E     -
Div/yield     -
EPS -0.65
Shares 38.78M
Beta 0.63
Inst. own 43%
Nov 13, 2014
Q3 2014 Response Genetics Inc Earnings Call
Nov 13, 2014
Q3 2014 Response Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -81.61% -40.50%
Operating margin -75.13% -40.13%
EBITD margin - -36.93%
Return on average assets -102.61% -46.30%
Return on average equity -416.21% -307.49%
Employees 109 -
CDP Score - -

Address

6th Floor, 1640 Marengo St.
LOS ANGELES, CA 90033
United States - Map
+1-323-2243900 (Phone)
+1-323-2243096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company�s technologies enable it to reliably and consistently extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and thereby to analyze genetic information contained in these tissues. The Company�s technologies also enable us to use the FFPE patient biopsies for the development of diagnostic tests. The Company provide tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric and gastroesophageal cancer (GE), melanoma and thyroid cancer, and breast cancer patients� tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid and ResponseDX: Breast test.

Officers and directors

Thomas A. Bologna Chairman of the Board, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Kevin R. Harris Chief Financial Officer, Vice President
Age: 45
Bio & Compensation  - Reuters
Stephanie H. Astrow Ph.D. Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Adanech Getachew General Counsel
Age: 37
Bio & Compensation  - Reuters
Kirk K. Calhoun Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael Serruya Director
Age: 49
Bio & Compensation  - Reuters
Sam Chawla Independent Director
Age: 39
Bio & Compensation  - Reuters
David R. Schreiber Independent Director
Bio & Compensation  - Reuters
Richard A. Van Den Broek Independent Director
Age: 48
Bio & Compensation  - Reuters